Journal
CURRENT PHARMACEUTICAL DESIGN
Volume 12, Issue 20, Pages 2557-2567Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/138161206777698792
Keywords
peptide inhibitors; beta-sheet breakers; amyloid; conformational disorders; Alzheimer's disease
Categories
Ask authors/readers for more resources
Several human diseases are associated with the presence of toxic fibrillar protein deposits. These diseases called protein misfolding disorders, are characterized by the accumulation of misfolded protein aggregates in diverse tissues. Strong evidence indicates that the conversion of a normal soluble protein into a P-sheet-rich oligomeric structure and further fibrillar aggregation are the key events in the disease pathogenesis. Therefore, a promising therapeutic target consists of the prevention and dissolution of misfolded protein aggregates. Peptides designed to specifically bind to the pathogenic protein and block and/or reverse its abnormal conformational change constitute a new class of drugs. This article reviews this approach, describing diverse compounds reported to have this activity.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available